Teva Pharmaceutical Industries (NYSE:TEVA) Coverage Initiated by Analysts at Leerink Partners

Stock analysts at Leerink Partners initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note issued to investors on Wednesday, Briefing.com reports. The firm set an “outperform” rating and a $45.00 price target on the stock. Leerink Partners’ price target indicates a potential upside of 21.51% from the stock’s previous close.

A number of other equities analysts have also recently commented on TEVA. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 28th. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, September 4th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings raised shares of Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 21st. Ten research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.10.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded up $0.27 on Wednesday, hitting $37.03. The company’s stock had a trading volume of 270,513 shares, compared to its average volume of 6,941,984. Teva Pharmaceutical Industries has a one year low of $18.21 and a one year high of $38.37. The firm has a market capitalization of $43.15 billion, a P/E ratio of 62.04, a price-to-earnings-growth ratio of 4.53 and a beta of 0.87. The stock has a fifty day moving average of $34.76 and a two-hundred day moving average of $33.31. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. The company had revenue of $4.14 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. Research analysts predict that Teva Pharmaceutical Industries will post 1.94 earnings per share for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Eliyahu Kalif sold 106,563 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the sale, the executive vice president owned 65,621 shares in the company, valued at $2,237,676.10. The trade was a 61.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. National Pension Service raised its holdings in Teva Pharmaceutical Industries by 4.9% in the 2nd quarter. National Pension Service now owns 2,406,013 shares of the company’s stock valued at $81,516,000 after acquiring an additional 112,357 shares in the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $33,799,000. IFP Advisors Inc boosted its position in shares of Teva Pharmaceutical Industries by 1.1% during the 2nd quarter. IFP Advisors Inc now owns 143,876 shares of the company’s stock worth $4,875,000 after acquiring an additional 1,532 shares in the last quarter. Waverly Advisors LLC increased its stake in Teva Pharmaceutical Industries by 7.7% in the second quarter. Waverly Advisors LLC now owns 12,814 shares of the company’s stock valued at $434,000 after acquiring an additional 918 shares during the last quarter. Finally, Nykredit A S bought a new position in Teva Pharmaceutical Industries in the second quarter valued at approximately $11,526,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in Jerusalem in 1901, the company develops, manufactures and markets generic medicines, specialty pharmaceuticals, biosimilars and active pharmaceutical ingredients.

Teva’s specialty medicines include treatments for multiple sclerosis, migraine, movement disorders and respiratory conditions. Its branded portfolio has included Copaxone, Ajovy, Austedo and Uzedy, while its generic medicines business provides products across a broad range of therapeutic areas and dosage forms.

The company serves patients, healthcare providers and pharmaceutical customers in markets across North America, Europe and other international regions.